Biotech in space?

Written byEdyta Zielinska

| 2 min read

Can the biotech and pharma make money in space? That was the question Congress posed at a hearing on the International Space Station's linkurl:future,;https://science.house.gov/press/PRArticle.aspx?NewsID=2167 held on Thursday (April 24). "I think I can," Tom Pickens, CEO of a spaceflight services company-turned biotech called SPACEHAB, told Congress. SPACEHAB has been sending up science payloads for the past 23 years. The company has mostly worked with government scientists, but when Pickens joined in 2003 as a member of the board of directors, he had a team of engineers assess what kinds of research would be most commercially viable. To fit the bill, experiments had to be cheap to transport and provide an advantage - in efficiency, quality or capability - over what could be done on Earth. Two methods stood out: growing crystals for X-ray crystallography, and linkurl:vaccine production.;https://www.the-scientist.com/news/home/53627/ So SPACEHAB is going from space transport to drug discovery. The company's "first product will be a vaccine," said Pickens. But will investors bite? So far, said Bruce Pittman, a founding member of the Alliance of Commercial Enterprises and Education for Space, a group of pro-commercial space advocates, he hasn't seen any venture capital investment in this area, a fact that Pickens concedes. However, Pittman told The Scientist, "The stars are beginning to align." On April 18th, Space Florida, the state's aerospace development organization, announced that it would linkurl:partner;https://www.spacehab.com/news/2008/08_04_21.htm with SPACEHAB to help spur biotech in space, and awarded the company $90,000 in seed funding. The money will retroactively support infectious disease experiments SPACEHAB sent up in March 2008, and the follow-up experiment to be launched in May, to validate those experiments. Deb Spicer, spokeswoman for Space Florida, said that if the experiments are deemed successful, the agency plans to approve a larger contract, which is likely to be upwards of $100,000. (The exact amount has yet to be released.) Congress wants linkurl:verification;https://www.the-scientist.com/news/home/53389/ "from someone that's not the science community" that conducting life science research in space can be lucrative, Pickens said. "The American people want a return on investment."

Biotech in space?

The Scientist ARCHIVES

Become a Member of

Meet the Author

Edyta Zielinska

Related Research Resources

Multiplex Microscopy Becomes Easier with Encoded Antibodies

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Best Practices for qPCR Assay Design and Optimization

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Building Translation-Ready Biomarkers with Connected Workflows

Products

Product News

The ASSIST PLUS pipetting robot for affordable workflow automation

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays